Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Former research took place at the Winthrop Laboratories site near the current Fawdon Metro station, which became Sanofi, on Edgefield Avenue in Fawdon; this site made Panadol and Solpadeine. In 1978 the company wanted to open a research site at Dukes House in Hexham , on a site of 38 acres, north of the building. [ 1 ]
It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. ... 800-290-4726 more ...
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the time ...
On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company ...
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, [6] and in January 2018, the City of New ...